Results 1 to 10 of about 591,821 (395)

Cardiac sympathetic dysfunction in pulmonary arterial hypertension: lesson from left-sided heart failure [PDF]

Pulmonary Circulation, 2019
Sympathetic nervous system hyperactivity has a well-recognized role in the pathophysiology of heart failure with reduced left ventricular ejection fraction.
Valentina Mercurio, Teresa Pellegrino, Giorgio Bosso, Giacomo Campi, Paolo Parrella, Valentina Piscopo, Carlo G. Tocchetti, Paul M. Hassoun, Mario Petretta, Alberto Cuocolo, Domenico Bonaduce   +10 more
doaj   +2 more sources

Clinical phenotyping of plasma thrombospondin-2 reveals relationship to right ventricular structure and function in pulmonary hypertension

ERJ Open Research, 2023
Background Converging evidence from proteogenomic analyses prioritises thrombospondin-2 (TSP2) as a potential biomarker for idiopathic or heritable pulmonary arterial hypertension (PAH).
Anna M. Dittrich, Julia Mienert, Julian Pott, Lena Engels, Christoph Sinning, Jan K. Hennigs, Hans Klose, Lars Harbaum   +7 more
doaj   +1 more source

Transcription factors in the pathogenesis of pulmonary arterial hypertension—Current knowledge and therapeutic potential

Frontiers in Cardiovascular Medicine, 2023
Pulmonary arterial hypertension (PAH) is a disease characterized by elevated pulmonary vascular resistance and pulmonary artery pressure. Mortality remains high in severe cases despite significant advances in management and pharmacotherapy.
Jakob Körbelin, Julius Klein, Julius Klein, Christiane Matuszcak, Christiane Matuszcak, Johannes Runge, Johannes Runge, Lars Harbaum, Hans Klose, Jan K. Hennigs, Jan K. Hennigs   +10 more
doaj   +1 more source

Sotatercept for the Treatment of Pulmonary Arterial Hypertension.

New England Journal of Medicine, 2021
BACKGROUND Pulmonary arterial hypertension is characterized by pulmonary vascular remodeling, cellular proliferation, and poor long-term outcomes.
M. Humbert, V. McLaughlin, J. Gibbs, M. Gomberg-Maitland, M. Hoeper, I. Preston, R. Souza, A. Waxman, Pilar Escribano Subías, J. Feldman, G. Meyer, D. Montani, K. Olsson, S. Manimaran, J. Barnes, P. Linde, J. de Oliveira Pena, D. Badesch   +17 more
semanticscholar   +1 more source

Residual risk identified in routine noninvasive follow-up assessments in pulmonary arterial hypertension

ERJ Open Research, 2023
Background The 2022 ESC/ERS guidelines on pulmonary hypertension recommend noninvasive risk assessments based on three clinical variables during follow-up in patients with pulmonary arterial hypertension (PAH).
Jonna Ostermann, Julian Pott, Jan K. Hennigs, Kevin Roedl, Christoph Sinning, Lars Harbaum, Hans Klose   +6 more
doaj   +1 more source

A cluster of heritable pulmonary arterial hypertension cases in a family with all three siblings carrying the same novel AQP1 c.273C>G variant‐a case report

Pulmonary Circulation, 2023
Approximately 25%–30% of patients diagnosed with idiopathic pulmonary arterial hypertension (PAH) have a clustered underlying Mendelian genetic cause and should be classified as heritable PAH (HPAH).
Kae‐Woei Liang, Sheng‐Kai Chang, Yu‐Wei Chen, Wan‐Jane Tsai, Kuo‐Yang Wang   +4 more
doaj   +1 more source

BMPR2 Mutation and Metabolic Reprogramming in Pulmonary Arterial Hypertension

Circulation Research, 2023
: Pulmonary arterial hypertension forms the first and most severe of the 5 categories of pulmonary hypertension. Disease pathogenesis is driven by progressive remodeling of peripheral pulmonary arteries, caused by the excessive proliferation of vascular ...
Iona Cuthbertson, N. Morrell, P. Caruso
semanticscholar   +1 more source

Caspase-4/11–Mediated Pulmonary Artery Endothelial Cell Pyroptosis Contributes to Pulmonary Arterial Hypertension

HYPERTENSION, 2022
Supplemental Digital Content is available in the text. Background: Endothelial dysfunction enhances vascular inflammation, which initiates pulmonary arterial hypertension (PAH) pathogenesis, further induces vascular remodeling and right ventricular ...
Yusi Wu, Bingjie Pan, Zhen Zhang, Xiao-hui Li, Yiping Leng, Yong Ji, Kun Sun, Alex F. Chen   +7 more
semanticscholar   +1 more source

Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension

European Respiratory Journal, 2022
Background In participants with pulmonary arterial hypertension, 24 weeks of sotatercept resulted in a significantly greater reduction from baseline in pulmonary vascular resistance than placebo.
M. Humbert, V. McLaughlin, J. Gibbs, M. Gomberg-Maitland, M. Hoeper, I. Preston, Rogério Souza, A. Waxman, H. Ghofrani, Pilar Escribano Subías, J. Feldman, G. Meyer, D. Montani, K. Olsson, S. Manimaran, J. de Oliveira Pena, D. Badesch   +16 more
semanticscholar   +1 more source

Transient but not genetic loss of miR-451 attenuates the development of pulmonary arterial hypertension [PDF]

, 2013
<b>Rationale:</b> MicroRNAs are small non-coding RNAs involved in the regulation of gene expression and have recently been implicated in the development of pulmonary arterial hypertension (PAH).
Baker, Andrew H., Dempsie, Yvonne, Grant, Jennifer S., MacLean, Margaret R., Morecroft, Ian, van Rooij, Eva   +5 more
core   +7 more sources